152811-81-9

Upstream product

• 67686-01-5 1-benzyl-4-piperidinemethanol 
• 203585-25-5 methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 

Downstream Products

• 1247008-47-4 [1-[[4-(2-methoxy-1,1-dimethyl-2-oxoethyl)phenyl]methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 
• 1247008-23-6 2-[4-[[4-(3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)-1-piperidinyl]methyl]phenyl]-2-methylpropanoic acid 
• 1247008-27-0 [1-[[4-[1,1-dimethyl-2-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]-2-oxoethyl]phenyl]methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate hydrochloride 
• 1247008-25-8 [1-[[4-[1,1-dimethyl-2-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]-2-oxoethyl]phenyl]methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 
• 1444006-50-1 [1-[(4-tert-butylphenyl)methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 

Relevant academic research and scientific papers

Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist

5-HT4 receptor antagonists have been suggested to have clinical potential in treatment of atrial fibrillation, diarrhea-prone irritable bowel syndrome and urinary incontinence. Recently, the use of 5-HT4 antagonists has been suggeste